A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Status:
Suspended
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a new drug called "nivolumab" as a possible treatment for
smoldering multiple myeloma in order to prevent or postpone development of active multiple
myeloma.
- Patients with smoldering multiple myeloma do not have symptoms but are at risk for
progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell,
which is an important part of the immune system. Patients with active multiple myeloma
generally require treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Blood Cancer Research Partnership Bristol-Myers Squibb Multiple Myeloma Research Consortium